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Protease protection assays of apolipoprotein 
B100 (apoB) in digitonin-permeabilized HepG2 cells 
indicated that multiple domains of apoB are exposed to 
the cytosol through an extensive portion of the secre-
tory pathway. The intracellular orientation of apoB in 
the secretory pathway was confirmed by immunocy-
tochemistry using antibodies recognizing specific do-
mains of apoB in streptolysin-O (STP-O)– and sapo-
nin-permeabilized HepG2 cells. Lumenal epitopes on 
marker proteins in secretory pathway compartments 
(p63, p53, and galactosyltransferase) were not stained 
by antibodies in STP-O–treated cells, but were brightly 
stained in saponin-treated cells, confirming that inter-
nal membranes were not perforated in STP-O–treated 
cells. An anti-apoB peptide antibody (B4) recognizing 
amino acids 3221–3240 caused intense staining in close 
proximity to the nuclear membrane, and less intensely 
throughout the secretory pathway in STP-O–permeabi-
lized cells. Staining with this antibody was similar in 
STP-O– and saponin-treated cells, indicating that this 
epitope in apoB is exposed to the cytosol at the site of 
apoB synthesis and throughout most of the remaining 
secretory pathway. Similar results indicating a cytosolic 
orientation were obtained with monoclonal antibody 
CC3.4, which recognizes amino acids 690–797 (79–91 
kD) in apoB. Two polyclonal antibodies made to hu-
man LDL and two monoclonal antibodies recognizing 
amino acids 1878–2148 (D7.2) and 3214–3506 (B1B6) in 
apoB did not produce a strong reticular signal for apoB 
in STP-O–treated cells. The anti-LDL and B1B6 anti-
bodies produced almost identical punctate patterns in 
STP-O–treated cells that overlapped with LAMP-1, a 
membrane marker for lysosomes. These observations 
suggest that the B1B6 epitope of apoB is exposed on 
the surface of the lysosome. The results identify two 
specific regions in apoB that are exposed to the cytosol 










derived from very low density lipoprotein (VLDL)
particles secreted by liver. In humans both VLDL
and LDL use apolipoprotein B100 (apoB) as the primary
structural protein. ApoB is a large secretory protein (540
kD) that contains hydrophillic domains that help solubi-
lize the lipoprotein in aqueous plasma and hydrophobic
amphipathic domains that bind lipids and enclose a neu-
tral core lipid droplet (Segrest et al., 1994). The human in-
testine and the livers of rats, mice, and dogs synthesize a





-terminal 2,152 amino acids of apoB (Innerarity et al.,
1996). As a secretory protein, apoB contains a cleavable
signal sequence, is synthesized on membrane-bound ribo-
somes, and is cotranslationally translocated through the
membrane of the ER (Dixon and Ginsberg, 1993; Innerar-
ity et al., 1996; Yao et al., 1997). ApoB-containing lipopro-
tein assembly then occurs in a putative two-step process in
which an initial lipoprotein particle is formed in the rough
ER (Borén et al., 1993; Borén et al., 1994) and expansion
of the lipid core then occurs in a second step in the smooth
ER (Alexander et al., 1976) or possibly the Golgi (Higgins,
1988).
Regulation of the secretion of apoB is primarily post-
translational (Borchardt and Davis, 1987; Dixon and Gins-
berg, 1993; reviewed in Yao et al., 1997). If lipid substrates
are limiting, a large percentage of newly synthesized apoB
molecules will be efficiently and rapidly degraded, either
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during or shortly after translation or after formation of an
immature nascent lipoprotein particle within the secretory
pathway (Dixon et al., 1991; Borén et al., 1994). When
neutral lipid availability is increased, more apoB will be
assembled into lipoprotein particles and secreted, and less
apoB will be degraded intracellularly. To understand the
transport of apoB in the secretory pathway, it is necessary
to study the location of apoB in the cell and its orientation
in the ER membrane. Although there is consensus that
apoB becomes associated with the inner leaflet of the ER
membrane, there is controversy concerning whether apoB
is a transmembrane protein in the ER or remaining secre-
tory pathway. Identifying apoB as a transmembrane pro-
tein represents a biological paradox because apoB con-
tains a cleavable signal peptide and becomes glycosylated
at multiple sites throughout the entire polypeptide. Addi-
tionally, although apoB is highly hydrophobic, it does not
have even one classical membrane-spanning domain (Knott
et al., 1986).
ApoB was identified as a cytosolically exposed protein
in the studies of Davis et al. (1990), who reported that
56% of apoB particles and 70% of apoB48 particles in
rough ER vesicles isolated from rat liver were sensitive to
exogenous trypsin. Dixon et al. (1992) showed that 60–
75% of newly labeled apoB in rough ER vesicles isolated
from chicken liver was susceptible to digestion with exoge-
nous proteinase K. Other studies, for the most part using
microsomes isolated through cell fractionation, have also
observed that regions of apoB are exposed on the cytoso-





al., 1992; Verkade et al., 1993; Wilkinson et al., 1993;
Borén et al., 1993; Du et al., 1994; Wang et al., 1995; Bon-
nardel and Davis, 1995; McLeod et al., 1996). Du et al.





 terminus of apoB resided in the lumen of micro-
somes, whereas the remaining domains of apoB were on
the cytoplasmic surface of the ER membrane in HepG2
cells. Newly synthesized apoB was shown to be 60–80%
cytosolically exposed in digitonin-permeabilized HepG2
cells (Macri and Adeli, 1997). Recently, apoB was found
to be associated with heat shock protein 70 (Zhou et al.,
1995), conjugated with ubiquitin (Yeung et al., 1996), and
targeted for degradation to the cytosolic proteasome
(Fisher et al., 1997). All of these observations strengthen
the likelihood that apoB becomes transmembrane at some
point in its transport through the secretory pathway.
However, other investigators have not observed a trans-
membrane orientation for apoB. A study in COS-1 cells
transfected with the entire amino-terminal 50% of apoB
indicated a complete lumenal localization of apoB in these
nonhepatic cells (Shelness et al., 1994). ApoB did not as-
sume an exposed cytosolic orientation after translation of
mRNA coding for apoB30 in the presence of dog pancreas
microsomes (Pease et al., 1995). In recent studies, a major-
ity of endogenous apoB was protected from exogenous
protease in membrane vesicles isolated from HepG2 cells
(Ingram and Shelness, 1996; Leiper et al., 1996). Also, the
extent of apoB glycosylation suggested that apoB was fully
translocated into the lumen of the ER (Wong and Torbati,
1994; Leiper et al., 1996).
The experiments described in the current report have
used both protease protection assays and immunocy-
tochemistry to explore the location and orientation of
apoB in the ER and in other compartments of the secre-
tory pathway. The combined data provide convincing evi-
dence that apoB, although most probably largely translo-
cated into the lumen of the ER during translation, does
assume a transmembrane orientation in the ER mem-
brane of HepG2 cells. Information on the transmembrane
nature of apoB may help in understanding regulation of













H]leucine (135 Ci/mmol, catalog no. TRK.683) was purchased from
Nycomed Amersham Inc. (Princeton, NJ). Protein A-Sepharose CL-4B was
obtained from Pharmacia LKB Biotechnology, Inc. (Piscataway, NJ).
Minimum essential medium, nonessential amino acids, sodium pyruvate,
streptolysin-O, and penicillin/streptomycin were from GIBCO BRL
(Gaithersburg, MD). Labeling of cells was performed with a leucine-free
medium generated from a minimum essential medium select amine kit
(catalog no. 300–9050AV; GIBCO BRL). Leupeptin and pepstatin A
were from Peninsula Laboratories, Inc. (Belmont, CA). BSA (essentially
fatty acid–free), FBS (F6761), bovine thrombin, and apoferritin from
horse spleen (A3641) were purchased from Sigma Chemical Co. (St.
Louis, MO). Digitonin (high purity, no. 300410) was from Calbiochem-









mol of tyrosine liberated per min




C), and Pefabloc were from Boehringer Mann-
heim Corp. (Indianapolis, IN). Monospecific anti–human LDL antibody
was raised in a rabbit. Sheep anti-human LDL was purchased from Sero-
tec Ltd. (Raleigh, NC). The CC3.4, D7.2, and B1B6 monoclonal antibod-
ies to apoB (domains shown in Fig. 1) were gifts of Dr. Gustav Schonfeld,
Washington University, St. Louis, MO. Monoclonal antibodies to p63
(G1/296) and p53 (G1/93) were gifts of Dr. Hans-Peter Hauri, Depart-
ment of Pharmacology, Biocenter of the University of Basel, Switzerland.
Rabbit polyclonal antiserum to human galactosyltransferase was a gift
from Dr. Eric G. Berger, Physiolog. Institut, Winterthurerstrasse 190, CH-8057
Zurich, Switzerland. Monoclonal antibody (H4A3) to lysosomal-associated
membrane protein-1 (LAMP-1) was purchased from the Developmental
Studies Hybridoma Bank, Department of Biological Sciences, The Uni-
versity of Iowa, Iowa City, IA. Antibodies conjugated with horseradish
peroxidase (AffiniPure™ goat anti–rabbit IgG and AffiniPure™ rabbit
anti–sheep IgG) were from Jackson Immuno Research Laboratories, Inc.
(West Grove, PA). All other chemicals were of the highest purity available.
 
Synthesis of Human apoB Peptides and Raising 
Antipeptide Antisera in Rabbits 
 
The SOAP program in PCGene was used to identify hydrophillic peptides
in human apoB that are adjacent to highly hydrophobic regions (Fig. 1).
Peptide names (amino acids in human apoB) are as follows: B1 (532–542):
-arg-lys-met-glu-pro-lys-asp-lys-asp-glu-glu; B2 (1113–1122): -glu-thr-lys-
asp-asp-arg-lys-ile-lys-gly; B3 (2059–2069) -lys-try-asp-lys-asn-gln-asp-val-
his-ser-ile; B4 (3221–3240): -lys-ser-tyr-asn-glu-thr-lys-ile-lys-phe-asp-lys-
tyr-lys-ala-glu-lys–ser-his-asp; and B5 (4010–4020): -gly-met-asp-met-asp-
glu-asp-asp-asp-phe-ser.
These peptides were synthesized on multiple antigenic peptides (MAP)
resins on a model 432A synthesizer (PE Applied Biosystems, Foster City,
CA) using Fmoc chemistry. Peptides were synthesized, cleaved, and puri-
fied according to the manufacturer’s protocol (PE Applied Biosystems).
Polyclonal antibodies to MAPs were prepared in New Zealand White
rabbits. After collecting preimmunized sera, each rabbit received a subcu-
taneous injection of a mixture of an individual peptide (0.5–1 mg) and
Freund’s adjuvant. The rabbits were boosted at 3–4-wk intervals with half
the quantity of peptide and Freund’s incomplete adjuvant. Before use in
immunocytochemistry, the B4 antipeptide antibody and the rabbit and
sheep polyclonal anti–human LDL antibodies were affinity-purified on
columns containing either purified peptide or human LDL, respectively.









 buffer, pH 7.0) was loaded onto a column consisting of 3 ml of
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aminolink-gel coupled with 2.78 mg of the B4 MAP. The column was








 buffer, pH 7.0, and eluted with 0.1 M
glycine buffer, pH 2.8. The B4 antibody was eluted in a peak of 3 ml total
volume. There was almost complete recovery of apoB immunoprecipita-
tion activity. Both rabbit and sheep polyclonal anti-human LDL were pu-
rified in the same way on columns containing aminolink gel coupled with
human LDL.
 
Metabolic Labeling of Cells, Permeabilization with 
Digitonin, and Immunoprecipitation 
 





/well) in complete growth medium (MEM with 0.1 mM nonessen-














For protease protection assay in permeabilized cells, medium was re-
moved from confluent wells, and the cells were washed twice with PBS
and preincubated for 1 h in serum-free medium containing 1.5% BSA. For
pulse labeling, the medium was removed, and the cells were washed with








Ci/ml) for 10 min. The labeling medium was removed, the cells were
washed twice with PBS, and serum-free chase medium was added for the
indicated time. At the end of the chase period, medium was removed and
cells were either harvested immediately or permeabilized with digitonin.
For harvesting, 1 ml of lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM
Tris, pH 7.4, 0.0625 M sucrose, 0.5% Triton X-100, and 0.5% sodium
deoxycholate) containing a protease inhibitor mixture (final concentra-
tions: 1 mM benzamidine, 5 mM EDTA, 0.86 mM phenylmethylsulfonyl
fluoride, 100 kallikrein-inactivating U/ml aprotinin, 10 mM 4-[2-hydroxy-












g/ml pefabloc) was added per well, and cells
were scraped off of the dish. For permeabilization, 1 ml of intracellular
buffer I (described by Plutner et al., 1992), 75 mM potassium acetate, 2.5 mM




, 1 mM ATP, and 25 mM









C. After 5 min, BB I containing digitonin was re-
moved, and the cells were washed three times with BB I alone. The cells





C with either BB I alone or BB I containing proteinase K (PK). After
incubation, PK was removed and the cells (which remained attached dur-
ing incubations and washes) were washed three times with BB I (1 ml).




C with 1 ml of lysis buffer










the method previously described (Yu et al., 1983; Dixon et al., 1991). A
small aliquot of each immunoprecipitate was taken for scintillation count-
ing, and samples were separated by SDS-PAGE (3–15% gradient; Laemmli,
1970). The gels were treated with Autofluor (National Diagnostic, Inc.,
Atlanta, GA) for 20 min, dried, and exposed to film (XAR-2; Eastman




Cells were grown to 90% confluence and washed with PBS, and proteins
were extracted with 2 ml of lysis buffer plus protease inhibitors. The pro-
teins were concentrated in a Centricon-10 concentrator (Amicon Corp.,
Eastman, TX), boiled in electrophoresis sample buffer, separated by SDS-
PAGE (3–15% gel), and transferred overnight from gels to polyvinyl di-
fluoride Immobilon P membranes (Towbin et al., 1979). After blocking
with 5% nonfat dried milk in Tris-buffered saline (0.02 M Trizma base,
0.137 M sodium chloride, pH 7.6) plus 0.02% Tween 20, membranes were
immunoblotted with antibodies (affinity-purified rabbit anti-human apoB
B4 peptide, 1/5,000 final dilution; sheep anti-human LDL, 1/10,000 final
dilution), and immunoreactive protein was visualized with horseradish
peroxidase–conjugated second antibodies (AffiniPure goat anti–rabbit
IgG and AffiniPure™ (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) rabbit anti–sheep IgG, 1/5,000 final dilution) and luminol re-
agent (ECL kit; Nycomed Amersham).
 
Culture of HepG2 cells for Immunocytochemistry and 
Permeabilization with Streptolysin-O
 
HepG2 cells were seeded onto collagen-coated coverslips and grown for









C. 1 h before fixing cells, the medium was changed to a serum-
free medium. For certain controls, cells were grown in serum-free medium
for 4 h before fixing. After 1 h in serum-free medium, the medium was as-
pirated and the cells were washed three times with intracellular buffer II
(designated BB II; 75 mM potassium acetate, 25 mM Hepes buffer, pH
7.2) that was modified after the buffer described by Plutner et al. (1992).









C with 500 U/ml
streptolysin-O (STP-O) dissolved in BB II. STP-O was removed, and the





for pore formation. STP-O permeabilizes the plasma membrane of hepa-
tocytes, allowing access of IgG molecules to domains of proteins exposed
on the cytosolic side of intracellular membranes without rupturing these
internal membranes (Ahnert-Hilger et al., 1989; Esparís-Ogando et al.,





C, and were blocked for 1 h with BB II plus 0.1% BSA. Permeabilized
cells were incubated for 4 h or overnight with primary antibodies (mono-
clonal, polyclonal, or antipeptide) to apoB or to control resident secretory
pathway proteins, followed by incubation for 4 h with the appropriate
anti–mouse, –rabbit, or –sheep IgG secondary antibody conjugated with
fluorochromes (Cy 3, indocarbocyanine or Cy 5, indodicarbocyanin; Jack-
son ImmunoResearch Laboratories, Inc., West Grove, PA). After wash-
ing and mounting coverslips onto glass slides, cells were examined with a
MRC-600 confocal microscope (Bio-Rad Laboratories, Hercules, CA) lo-
cated in the Molecular Cytology Core Laboratory supported by the Uni-
versity of Missouri.
 
Saponin Permeabilization of Cells
 
In addition to STP-O permeabilization, cells were also permeabilized with
saponin in order to expose lumenal epitopes of both apoB and marker
proteins that remained hidden in STP-O–permeabilized cells. Saponin is an
agent that forms holes in membranes, but does not extract membrane pro-
teins. Saponin allows access of antibody molecules to epitopes that are lu-
menal and accessible. If epitopes are hidden by lipids or by protein con-
formation, they may not be recognized by an antibody in saponin-treated
cells. After fixing cells with 2% paraformaldehyde and washing three times
with BB II, the cells were treated with 0.1% saponin in BB II plus 0.1%




C. The cells were then washed with 0.1% saponin in
BB II plus 0.1% BSA. All incubations of cells with primary and secondary
antibodies and washes were done with 0.1% saponin in BB II plus 0.1% BSA.
 
Analysis of Digitized Images 
 
To compare and determine quantitative differences in fluorescence im-
ages obtained between treatments with the confocal microscope, it was
necessary to compare the total spectrum of pixel intensity in specific areas
of cells in fields of cells of similar cell density. All other experimental con-
ditions were kept constant, including antibody titre, total cell confluence,
laser strength, magnification, and basal instrument settings. In the current
study, the approximate signal strength for apoB in the ER of STP-O–per-
meabilized cells was compared with that in saponin-permeabilized cells.













m–wide area around the nucleus of
each cell and obtaining a histogram of pixel intensity for all pixels within
this region. The fluorescence signal was calculated by obtaining the inte-
grated sum of all pixel values in the histogram. This sum of all pixel values




m bounded region to

























cells with different permeabilization treatments were compared in order
to determine whether the relative signal intensities differed between treat-
ments. The signal obtained in saponin-treated cells was taken as the total
epitope exposed both to the cytosol and lumen, and was set at 100%. The
signal obtained in STP-O–permeabilized cells was considered to be only
exposed to the cytosol. The fluorescence signal due to lumenal epitopes









STP-O alone, but the fluorescence due to cytosolic epitopes should




Synthesis of apoB Peptides as MAP Conjugates and 
Production of Antipeptide Antibodies
 
A hydrophobicity plot of the amino acid sequence of hu-
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man apoB was examined in order to identify hydrophillic
segments of apoB that are adjacent to highly hydrophobic
regions (Fig. 1). Five hydrophillic segments were chosen
(B1–B5), and these peptides were synthesized as MAP
conjugates as described in Materials and Methods. Rabbit











H]apoB (Fig. 2) with high specificity and ti-
tre. The B2 antibody could be purified on a B2 peptide
column, but did not recognize the corresponding domain
in the apoB molecule (data not shown). Fig. 2 shows that
the antibody to the B4 peptide (later referred to as the B4
antibody) immunoprecipitated apoB (lower band) with
good efficiency compared with a rabbit polyclonal anti-
body made to human LDL. The protein that migrated
slower than the apoB standard has been identified as ag-
gregated apoB, and was immunoprecipitated by both poly-
clonal and B4 antibodies.
 
Immunoblot Analysis of the B4 Antibody
 
HepG2 cell proteins solubilized by lysis buffer were elec-
trophoresed and blotted to a polyvinyl difluoride mem-
brane and probed by an affinity-purified preparation of B4
antibody (Fig. 3). The results show that the B4 antibody
was highly specific for apoB. Light bands at other molecu-
lar weights were shown by comparison with other anti-
apoB antibodies to be breakdown products of full-size
apoB (data not shown). The polyclonal antibody made to




70 kD, the major small degradation product of apoB
seen in cells and medium (Adeli, 1994; Du et al., 1994).
 












permeabilized HepG2 cells was investigated by protease
protection assay after a 10-min pulse/10-min chase (Fig. 4).




40 min to see significant secretion of newly
synthesized apoB (Dixon et al., 1991), most labeled apoB
was still probably located in the ER. Digitonin was used to
permeabilize cells in this experiment as STP-O (GIBCO










g/ml) was included in the assay buffer as
a carrier protein in lieu of BSA. Certain wells of cells were









norleucinal (ALLN) for 1 h before labeling in order to
prevent endogenous degradation of large apoB peptides
formed when apoB in permeabilized cells was initially cut








 (Fig. 4) show that
apoB immunoprecipitated from intact cells immediately
after the 10-min chase migrated at the same mobility as








) had a greater apoB signal intensity due to inhibi-
tion of very early apoB degradation during the pulse/chase





due to the permeabilization process or subsequent 40-min








). Unlike when iso-
lated microsomes are used to determine sidedness, close to
100% of labeled apoB can be probed in permeabilized
cells. After the incubation with PK, protease activity was
inhibited by adding protease inhibitors including phenyl-
methylsulfonyl fluoride. ApoB and degradation peptides
from apoB were immunoprecipitated with the sheep poly-
Figure 1. Structure of
apoB100. The structure shows
the locations of the B1–B5
epitopes and the CC3.4,
D7.2, and B1B6 monoclonal
antibody-binding domains
(Krul et al., 1988). Also
shown are putative trans-
membrane helices (TM), hy-
drophobic domains of fif-
teen amino acids or more
(j), and amphipathic helices
(boxed loops; Segrest et al.,
1994). The top scale is the
amino acid number while the
bottom scale represents apoB
using the centile system.
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clonal anti-LDL antibody. Incubation of permeabilized




























































). More consistent degradation
band patterns were observed after PK digestion in cells
that had been pretreated with ALLN compared with cells
not treated with ALLN (data not shown). Increasing the




g/ml led to partial loss of









most likely due to an inability to adequately inhibit pro-
tease activity during sample processing for immunoprecip-
itation (data not shown). When permeabilized cells were
incubated with thrombin, a large thrombin breakdown








) only in the
presence of Triton X-100. This product was identified as
387 kD based on the major thrombin site in apoB, T3/T2
(Krul et al., 1988). One of the major large apoB degrada-













) was identical in mobility to the major









tion of a distinct pattern of mainly large peptides in the
presence of ALLN suggests that PK had access to nascent
apoB at only a few sites, and that cleavage at one of the
sites caused the major peptides at 387 and 150 kD. The re-
Figure 2. Comparison of anti-apoB peptide antibodies to the
conventional polyclonal anti-LDL in ability to immunoprecipi-
tate apoB. Five hydrophilic peptides of apoB (B1–B5) were syn-
thesized as described in Materials and Methods. Polyclonal anti-
sera to these peptides were raised in rabbits and evaluated by
immunoprecipitation of [3H]leucine-labeled HepG2 proteins.
[3H]apoB from 500 ml of HepG2 lysis buffer cell extracts was im-
munoprecipitated with 1 ml of sheep polyclonal anti-human LDL
(poly, leftmost lane) or with 20 ml of each antipeptide antisera
under normal immunoprecipitation conditions (lanes designated
with a 1), or when the immunoprecipitation binding and washing
buffers contained final concentrations of 2 mM dithiothreitol and
0.5% deoxycholic acid (lanes designated with a 2). In the lane
marked 19, apoB was immunoprecipitated with 5 ml of the B4 an-
tiserum under normal immunoprecipitation conditions. ApoB
was immunoprecipitated and analyzed by SDS-PAGE (3–15%
gel) and fluorography. Markers show the location of Coomassie-
stained standard apoB (isolated from human plasma) and molec-
ular weight standards (kD). Antiserum from the rabbit injected
with the B4 peptide was affinity-purified on an aminolink-B4
peptide affinity column before use in subsequent immunocy-
tochemistry studies.
Figure 3. Western blot analy-
sis of HepG2 cell proteins us-
ing the B4 antibody. HepG2
cell proteins were solubilized
in lysis buffer, separated by
SDS-PAGE (3–15% gradient),
blotted to membranes, and
probed by the sheep poly-
clonal anti-human LDL anti-
body (P) or the affinity-puri-
fied B4 antibody (B4). Markers
show the location of Coo-
massie-stained standard apoB
(isolated from human plasma)
and molecular weight stan-
dards.
sults indicate that immediately after its complete biosyn-
thesis, apoB is a transmembrane protein with only a lim-
ited number of sites exposed on the cytosolic face of ER
membrane.
ApoB Topology Through the Secretory Pathway
Studies on apoB orientation (Fig. 5) were carried out at
longer chase times in order to test the hypothesis that
apoB translocates through the membranes of the secretory
pathway or changes its orientation in the membrane upon
formation of nascent lipoprotein particle in the ER. An al-
ternate hypothesis is that apoB retains a transmembrane
orientation even after partial lipidation and extensive
transport through the secretory pathway. In the experi-
ment depicted in Fig. 5, cells were treated with 40 mg/ml
(104 mM) ALLN in order to slow rapid intracellular apoB
degradation (Sakata et al., 1993) and to preserve the large
fragments of apoB formed by PK digestion of permeabi-
lized cells as seen in Fig. 4. Cells were labeled with
[3H]leucine as in Fig. 4, except that cells were chased for
either 10, 20, 30, 40, or 60 min before cell harvest or per-
meabilization. Additionally, certain cells destined for
longer chase periods were treated with 0.4 mM oleate
(OA) after the 10-min chase time point in order to test
whether increased lipid synthesis alters the conformation
of apoB in secretory pathway membranes. The permeabi-
lization protocol in the current experiment was similar to
that used for lanes 5–7 of the previous experiment (Fig. 4).
Although cells were treated with ALLN, there was endog-
enous posttranslational degradation of apoB during the
first 30 min of chase in nonpermeabilized cells (Fig. 5, A
and C). The decay in cellular [3H]apoB was much slower
in ALLN-treated cells compared with cells not treated
with ALLN (Fig. 5 C). Taking the amount of [3H]apoB in
cells after 10 min of chase as 100%, the decay in cellular
[3H]apoB was similar in ALLN-treated control and oleate-
treated cells. Decay in cellular apoB between 10 and 30
min was due to intracellular degradation. The decay in
apoB in oleate-treated cells between 30 and 60 min repre-
sented loss of cellular apoB primarily due to secretion,
whereas the decay in control cells was due to both degra-
dation and secretion during this period. After 60 min of
chase, 45–55% of labeled apoB was still present intracellu-
larly (Fig. 5 C). The dashed line in Fig. 5 C represents data
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from a previous experiment (Dixon et al., 1991) in which
apoB decay was monitored in control cells that were not
treated with ALLN. Only 15 6 3% of cellular [3H]apoB
remained after 60 min of chase in control cells not treated
with ALLN (Dixon et al., 1991). In the current experiment
there was 54% total recovery (cellular 1 medium) of
[3H]apoB in control cells, and 75% total recovery in ole-
ate-treated cells. This translates into 46% total degrada-
tion of [3H]apoB in control cells and 25% total degrada-
tion in oleate cells. The apoB degradation observed occurred
largely by an ALLN-independent proteolytic system, with
more degradation occurring in control cells.
The percentage of cellular full-size apoB that was sus-
ceptible to PK in permeabilized cells remained constant at
each of the chase time points (Fig. 5 D). At each of the
chase points, the pattern of apoB peptides observed after
PK digestion (Fig. 5 A; lanes 3, 6, 9, and 12) was similar to
the pattern observed in lane 7 of Fig. 4. One possible ex-
ception was that there may have been a slightly lower sig-
nal for full-size apoB (540 kD) and peptide 2 (450–470
kD) in control cells compared with oleate-treated cells af-
ter 30 or 40 min of chase (Fig. 5 A). That access of PK to
apoB was not the result of disruption of secretory pathway
membranes was most clearly evident at 10, 20, and 30 min
of chase when there was minimal loss of [3H]albumin from
the secretory pathway (4.5–9.7%; Fig. 5 B). Loss of
[3H]albumin due to the permeabilization process (Fig. 5 B)
was 9.7% at 10 min (lanes 2 and 5 compared with lanes 1
and 4), 4.5% at 20 min (lanes 8 and 11 compared with
lanes 7 and 10), and 6% at 30 min (lanes 2 and 5 compared
with lanes 1 and 4). In contrast, loss of [3H]albumin from
permeabilized cells was 29.5% at 40 min (lanes 8 and 11
compared with lanes 7 and 10) and 43% at 60 min (lanes 2
and 5 compared with lanes 1 and 4). These results indicate
that membranes of the later secretory pathway (possibly
trans Golgi or secretory vesicles) were more sensitive to
treatment with digitonin than were membranes of the ear-
lier secretory pathway (RER/SER), possibly because down-
stream membranes contain more cholesterol (Bretscher
and Munro, 1993). In cells that were chased for 60 min,
close to 100% of the labeled albumin that was initially
present in the cells was secreted into the medium (Fig. 5 B,
compare medium lanes 7–12 at 60 min with cellular lanes
1–6 at 10 min). The results show that membrane damage
can be precisely monitored in digitonin-permeabilized
cells by following loss of [3H]albumin from the lumen of
the secretory pathway to washes of the permeabilized
cells. The results also show that there was little difference
in the conformation of apoB in secretory pathway mem-
branes between control and oleate-treated cells between
10 and 30 min of chase. This was the case even though
there was a large stimulation in apoB secretion due to add-
ing oleate at the 10-min chase time point (Fig. 5, A and C).
The results indicate that apoB maintains its transmem-
brane orientation through at least 30 min of chase, and
that formation of a nascent lipoprotein particle does not
alter its transmembrane nature.
Confirmation of the Transmembrane Nature of apoB
by Immunocytochemistry
The sensitivity of apoB to exogenous protease in protease
protection assays is the primary basis for claims that apoB
becomes a transmembrane protein at some point after its
complete biosynthesis (for review see Yao et al., 1997).
One of the criticisms of such studies is that apoB is highly
susceptible to proteolysis, and that problems such as mem-
brane permeability, overdigestion, or incomplete inhibi-
tion of exogenous protease are difficult to control ade-
quately (Ingram and Shelness, 1996). To confirm that
domains of apoB are present on the cytosolic side of ER
membranes, cells were permeabilized with STP-O and
then probed with specific antibodies to apoB and exam-
ined with the confocal microscope. First, experiments
were performed to show that internal membranes were
not perforated in HepG2 cells treated with STP-O. HepG2
cells were fixed in paraformaldehyde, permeabilized with
either STP-O (Fig. 6, left) or saponin (Fig. 6, right), and
probed with antibodies to lumenal domains of resident
Figure 4. Sensitivity of apoB to proteinase K in digitonin-perme-
abilized cells. HepG2 cells were labeled with [3H]leucine and
chased as described in Materials and Methods. Cells in lanes 5–10
were preincubated for 1 h with 40 mg/ml (104 mM) ALLN, and
were also treated with ALLN during the pulse/chase periods. Af-
ter the chase cells were harvested immediately in lysis buffer
(lanes 1 and 5), or were permeabilized with 60 mg/ml digitonin
(DIG; lanes 2–4 and 6–10). Permeabilized cells were incubated
for 40 min at 48C with either BB I 1 100 mg/ml apoferritin (lanes
2 and 6), BB I 1 100 mg/ml apoferritin 1 proteinase K (PK; lane
7: 1.4 mg/ml; lane 8: 4.2 mg/ml; lane 9: 10 mg/ml; lane 10: 50 mg/
ml), or BB I 1 100 mg/ml apoferritin 1 bovine thrombin (Th; 7.56
U/ml or 0.14 mg/m; lanes 3 and 4). Cells in lane 4 were also incu-
bated in 1% Triton X-100 (TX). After removing PK, the cells
were washed three times and harvested in lysis buffer containing
protease inhibitors, and [3H]apoB was immunoprecipitated and
analyzed by SDS-PAGE (3–15% gel) and fluorography. Markers
show the location of Coomassie-stained standard apoB (isolated
from human plasma) and molecular weight standards. The right-
facing arrow to the left of lane 4 (arrow 8) shows the location of
the major thrombin cleavage product at 387 kD. Arrow 3 shows
the PK cleavage product that has the same mobility as the major
thrombin cleavage product. ApoB peptides formed by PK were
observed at z450–470 (arrow 2), 387 (dark band at arrow 3),
200–300 (arrow 4), 153 (dark band at arrow 5), 120 (arrow 6), and
60–70 kD (arrow 7).
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Figure 5. Time course of apoB topology in the secretory pathway of HepG2 cells. (A and B) Cells were preincubated for 1 h in serum-
free medium containing 40 mg/ml (104 mM) ALLN. ALLN was also present in the medium of all cells during the pulse and chase peri-
ods. Cells were pulsed with [3H]leucine for 10 min as described in Materials and Methods. After the pulse, all cells were chased for 10
min with serum-free medium containing 1.5% BSA. At this point, the 10-min chase cells were harvested, and the medium on all of the
other plates was changed to serum-free medium containing either 1.5% BSA (C, control; lanes 1–3 and 7–9) or 0.4 mM oleate com-
plexed to 1.5% BSA (OA; lanes 4–6 and 10–12). The remaining cells were then chased for a total of 20, 30, 40 or 60 min. After each
chase period the cells were either harvested immediately in lysis buffer (S, lanes 1, 4, 7, or 10) or permeabilized with 60 mg/ml digitonin
(B or PK, lanes 2, 3, 5, 6, 8, 9, 11, and 12) as described in Materials and Methods. After washing away the digitonin, permeabilized cells
were incubated for 40 min at 48C with either buffer (BB I) 1 100 mg/ml apoferritin (B; lanes 2, 5, 8, and 11) or with BB I 1 100 mg/ml
apoferritin 1 2.8 mg/ml proteinase K (PK, lanes 3, 6, 9, and 12). After 40 min of incubation, the buffer was removed, the cells were
washed three times with PBS and harvested in lysis buffer containing protease inhibitors. ApoB (A) or albumin (B) were immunopre-
cipitated and analyzed by SDS-PAGE (3–15% gel) followed by fluorography. The lower series of lanes 7–12 in each panel are apoB (A)
and albumin (B) immunoprecipitated from medium of cells that were chased for 60 min (corresponding cell extracts are in lanes 1–6 of
each lower series). Markers show the location of Coomassie-stained human plasma apoB and molecular weight standards. (C) Analysis
of time course of apoB decay. The fluorograms shown in A were scanned by laser densitometry, and the cellular apoB signal remaining
after each chase period is plotted in C. ApoB signal in nonpermeabilized cells (S in Fig. 5 A) is denoted for control cells (j) and for cells
treated with oleate (O). For permeabilized cells incubated with buffer alone (B in Fig. 5 A), the data is denoted for control cells (r) and
for cells treated with oleate (n). The data denoted (encircled 1) is the decay of apoB in control cells not treated with ALLN as reported
previously (Dixon et al., 1991). The bars on the right side of Fig. 5 C represent the amount of apoB secreted by control cells (closed bar)
or oleate-treated cells (open bar) after 60 min of chase (as a % of the initial cellular [3H]apoB after 10 min of chase). (D) The percentage
of apoB that was susceptible to PK digestion in control (open bar) and OA-treated cells (closed bar) after each chase period (expressed
as percent of the apoB signal at each time point). This experiment was repeated several times with similar results.
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marker proteins of different secretory pathway compart-
ments. The marker proteins were as follows: p63 (a
marker for the ER; Schweizer et al., 1995), p53 (a marker
for the ER-to-Golgi intermediate compartment; ERGIC;
Schweizer et al., 1995), and galactosyltransferase (a marker
for the Golgi; Berger et al., 1993). None of the lumenal
epitopes were accessible in STP-O–permeabilized cells
(1a, 2a, and 3a), but all were exposed in cells permeabi-
lized with saponin (1a, 2b, and 3b). To demonstrate that
the cells were in focal plane, STP-O–permeabilized cells
were also observed under bright-field conditions (1a, left).
P63 is a type II integral membrane protein that is predom-
inantly localized in the rough ER, but is absent from the
nuclear membrane and the cis-Golgi region (Schweizer et
al., 1995). In saponin-treated HepG2 cells (Fig. 6, 1b), the
p63 antibody stained an area around the nucleus as well as
a vast reticular network throughout the cell. The p63 anti-
body did not label the nuclear outer membrane as there
was no bright continuous line of staining surrounding the
nucleus. The p53 antibody stained a finite area of the cell
that resembled a crown (Fig. 6, 2b). This area was usually
located on one side of the nucleus and extended from the
nuclear region to the vicinity of the plasma membrane.
P53 is a marker for the ERGIC (usually located in the tu-
bulovesicular membranes at the cis face of the Golgi appa-
ratus). It is also present in the rough ER as p53 is postu-
lated to cycle between the ER and ERGIC (Schweizer et al.,
1995). The antibody to galactosyltransferase stained a
reticulum network that was removed from the nuclear
area, and that was in close proximity to the plasma mem-
brane. Galactosyltransferase is predominantly localized in
trans cisternae of the Golgi apparatus (Berger et al., 1993).
In the current experiments, the Golgi appeared to be lo-
cated in a more peripheral area of the cell. In agreement
with published reports (Ahnert-Hilger et al., 1989; Es-
parís-Ogando et al., 1994; Pimplikar et al., 1994), observa-
tions with all three markers indicated that intracellular
membranes were not perforated in STP-O–permeabilized
HepG2 cells.
Immunocytochemistry of apoB in HepG2 Cells
HepG2 cells were permeabilized with either STP-O (Fig.
7, A, C, and E) or saponin (Fig. 7, B, D, and F), blocked
with buffer plus 0.1% BSA, and incubated with the follow-
ing antibodies: (A, B) monoclonal anti-p63; (C, D) affin-
ity-purified rabbit anti-B4 peptide; (E, F) affinity-purified
polyclonal sheep anti-human LDL). After washing and ad-
ditional blocking, cells were treated with the appropriate
secondary antibodies conjugated with either Cy-3 or Cy-5
and examined with a confocal microscope. In preliminary
experiments, it was shown that there was extremely low
background fluorescence in cells that were: (a) nonperme-
abilized and treated with antibody B4 and secondary anti-
body; (b) permeabilized and treated with preimmune se-
rum and secondary antibody; or (c) permeabilized and
treated with primary antibodies alone (data not shown).
The lack of significant signal for p63 in STP-O–permeabi-
lized cells (Fig. 7 A) indicates that membranes of the endo-
plasmic reticulum were not permeabilized in this experi-
ment. The p63 signal was greatly increased when cells
were permeabilized with saponin (Fig. 7 B). In contrast,
the signal for apoB probed with the B4 antibody was sim-
ilar in both STP-O–permeabilized cells and saponin-
treated cells (compare C and D). Image analysis of the flu-
orescent signals for apoB in the perinuclear region of cells
(defined as a 2 mm–wide band starting with the transition
from relative blackness of the nuclear area to fluorescence
and radiating out toward the periphery of the cell) was
performed, and the mean and standard deviation of total
integrated pixel intensities/mm2 (TIPI/mm2) for three cells
from each treatment group was calculated. STP-O–treated
cells (Fig. 7 C) had a TIPI/mm2 5 3178 6 155 (mean 6
SD) compared with 3564 6 83 for saponin-treated cells
(Fig. 6 D). Therefore, the relative signal intensity for the
B4 antibody in STP-O–treated cells was 89% that of sapo-
nin-treated cells, indicating that the B4 antibody had ac-
cess to most B4 epitopes regardless of whether internal
membranes were permeabilized or not. Equivalent signal
intensities for apoB with the B4 antipeptide antibody were
observed in STP-O– and saponin-treated cells in six sepa-
rate experiments. These data indicate that the B4 epitope
in this region is exposed primarily on the cytosolic surface
of the ER membrane. In addition to giving a very strong
fluorescence in a bright continuous line surrounding the
nucleus, the B4 antibody stained the entire reticular net-
work throughout the cell in STP-O–treated cells (Fig. 7 C).
Figure 6. Membranes of the ER, ER-to-Golgi intermediate com-
partment, and the Golgi are left intact when the plasma mem-
brane of HepG2 cells is permeabilized with STP-O. HepG2 cells
were fixed in paraformaldehyde and permeabilized with either
STP-O (1a, 2a, and 3a) or saponin (1b, 2b, and 3b). The cells were
then probed with a 1/1,000 dilution of a monoclonal antibody to
p63 (a marker for the ER; 1a and 1b), a 1/1,000 dilution of a mon-
oclonal antibody to p53 (a marker for the ER to Golgi intermedi-
ate compartment; 2a and 2b), and a 1/50 dilution of a rabbit anti-
human galactosyltransferase (a marker for the Golgi; 3a and 3b).
The appropriate secondary antibodies were used at a dilution of
1/100. The left side of 1a is a bright-field image.
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The brighter fluorescence observed in the area in close
proximity to the nucleus in both STP-O– and saponin-
treated cells probably represents a higher concentration of
apoB at the primary location of apoB synthesis. We have
previously established that there is rapid degradation of
apoB in control HepG2 cells such that more than 50% of
newly synthesized [3H]apoB was degraded between 10 and
20 min of chase without isotope after a 10-min pulse pe-
riod with [3H]leucine (Dixon et al., 1991). The less intense
fluorescent signal that is observed in areas of the cell away
from the nuclear membrane represents apoB in the secre-
tory pathway (ER, ERGIC, and Golgi compartments). We
interpret the decrease in fluorescence signal in membranes
removed from the perinuclear region to result from a
lower concentration of apoB in these regions because of
degradation of apoB in the ER. The weaker signals away
from the perinuclear area may also be consistent with
some translocation of apoB across the ER on the way to
secretion.
Unexpectedly, there was no intense region of staining in
the perinuclear area of STP-O–treated cells probed with
the sheep anti-LDL antibody (Fig. 7 E). Instead, the poly-
clonal anti-LDL antibody gave a punctate staining pattern
with bright focused areas of signal scattered throughout
the cytoplasm of the cell (Fig. 7 E). Similar observations
were made in cells grown in serum-free medium for 4 h.
When interior membranes were permeabilized with sapo-
nin, an apoB signal was seen throughout the extensive
secretory pathway (Fig. 7 F). The labeling pattern ob-
tained with sheep anti-LDL in saponin-treated cells was
similar to that observed with the B4 antibody in saponin-
treated cells (Fig. 7 D), except for the absence of the in-
tense, narrow band of signal in the perinuclear region. A
lack of a defined perinuclear signal by the polyclonal anti-
LDL antibody in saponin-treated cells may have resulted
from the absence of mature epitope sites in nascent apoB
molecules recognized by this antibody (see Discussion).
These results demonstrate that none of the epitopes recog-
nized by the polyclonal anti-LDL antibody are exposed to
the cytosol in the perinuclear region of STP-O–treated
cells, and only become exposed after saponin permeabili-
zation. These data also confirm the earlier observation
that the membranes of the secretory pathway were not
ruptured in STP-O-permeabilized cells.
Orientation of Other Sites in apoB
The orientation of two other sites in apoB was tested by
immunocytochemistry. The CC3.4 monoclonal antibody
(Krul et al., 1988) that recognizes apoB within the region
Figure 7. Immunocytochem-
istry of apoB in HepG2 cells.
HepG2 cells were fixed in
2% paraformaldehyde and
permeabilized with either
STP-O (A, C, and E) or sa-
ponin (B, D, and F) and
probed with the following
antibodies: (A and B) mono-
clonal anti-p63 (1/1000); (C
and D) affinity-purified rab-
bit anti-human apoB peptide
B4 (1/100; recognizes apoB
between amino acids 3221
and 3240); and (E and F)
affinity-purified polyclonal
sheep anti-human LDL (1/
250). The appropriate sec-
ondary antibodies were used
at a dilution of 1/100.
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of amino acids 690–797 (79–91 kD) and the D7.2 mono-
clonal antibody (Krul et al., 1988) that recognizes apoB
within the region of amino acids 1878–2148 (216–247kD)
were used to probe apoB orientation in STP-O– and sapo-
nin-permeabilized cells. The CC3.4 antibody produced
bright staining in close proximity to the nucleus and in pe-
ripheral areas in STP-O–permeabilized cells (Fig. 8 A).
The bright staining near the nucleus was less defined com-
pared with the staining produced by the B4 antibody (Fig.
7 C). The signal produced by the CC3.4 antibody was not
greatly increased in saponin-permeabilized cells (Fig. 8 B).
There was almost a complete absence of intracellular sig-
nal when STP-O–permeabilized cells were probed with
the D7.2 antibody (Fig. 8 C). In contrast, a strong fluores-
cent signal was seen throughout saponin-treated cells (Fig.
8 D). These results indicate that the region of apoB identi-
fied by the CC3.4 antibody is exposed to the cytosol in the
perinuclear region and throughout the secretory pathway,
whereas the region identified by the D7.2 monoclonal an-
tibody most likely is not cytosolically exposed but located
in the lumen of the secretory pathway. Except for areas of
punctate staining in CC3.4-treated cells, the signals pro-
duced by the B4 and CC3.4 antibodies overlapped in both
perinuclear and cytosolic areas of STP-O–permeabilized
HepG2 cells (Fig. 9). These results show that two regions
of apoB that are widely separated are exposed to the cyto-
sol in extensive regions of the secretory pathway but that a
domain in between (the D7.2 region) is lumenal.
Colocalization of apoB with Monoclonal Antibody
B1B6 and Sheep Polyclonal Anti-human apoB 
The punctate labeling observed for apoB in STP-O–per-
meabilized cells using affinity-purified sheep polyclonal
anti-human LDL (Fig. 7 E) may have been due to a non-
specific interaction. Therefore, other antibodies to apoB
were used to confirm the labeling pattern of the sheep
polyclonal anti-LDL. STP-O–permeabilized HepG2 cells
were probed simultaneously with the sheep polyclonal
anti-LDL (Fig. 10 A) and with monoclonal antibody B1B6
(Fig. 10 B) that recognizes amino acids 3214–3506 in apoB
(Krul et al., 1988). After washing, the cells were incubated
with the appropriate secondary antibodies. Both the sheep
polyclonal anti-LDL antibody and monoclonal B1B6 pro-
duced signals in a punctate pattern in identical intracellu-
lar locations in STP-O–permeabilized cells (Fig. 10, A and
B). The digital images were compared, and significant
overlap is shown as yellow in Fig. 10 C. An overlapping
punctate pattern was also obtained when cells were
probed simultaneously with affinity purified rabbit and
sheep polyclonal anti-LDL antibodies (data not shown).
Colocalization of Punctate apoB Staining with the 
Lysosomal Marker LAMP-1
The punctate staining pattern observed with both the
polyclonal anti-LDL and B1B6 monoclonal anti-apoB an-
tibodies did not colocalize with antibodies to catalase or
an antibody to peroxisomal membrane proteins (data not
shown), ruling out that these signals of apoB were in per-
oxisomes. The punctate staining pattern did colocalize
with LAMP-1, a lysosomal membrane glycoprotein (Mane
et al., 1989). There was almost total overlap (Fig. 10 F) in
the signals for the sheep polyclonal anti-human LDL (Fig.
10 D) and for anti-LAMP-1 (Fig. 10 E) in cells that were
permeabilized with STP-O. The punctate pattern that was
observed for the antibodies may represent apoB or por-
tions of apoB that have been delivered to lysosomes. Ad-
ditionally, as observed for epitopes of apoB recognized by
the polyclonal anti-LDL antibody (Fig. 7 E), the epitope
of apoB that binds the B1B6 monoclonal antibody (Fig.
10 B) was hidden throughout most of the secretory path-
way, and only became exposed on or near the surface of
the lysosome.
Figure 8. Cellular orienta-
tion of CC3.4 and D7.2 do-
mains of apoB in HepG2
cells. Hep G2 cells were fixed
and permeabilized with ei-
ther STP-O (A and C) or sa-
ponin (B and D) and probed
with the following antibod-
ies: A and B: monoclonal
anti-human apoB CC3.4 (1/
100); C and D: monoclonal
anti-human apoB D7.2 (1/
500). The appropriate sec-
ondary antibodies were used
at final dilution of 1/100.
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Discussion
The ER of cells has been subdivided into three distinct but
continuous compartments: the nuclear envelope, the ribo-
some-containing rough ER, and the smooth ER (Palade,
1975). The current studies using an anti-apoB peptide anti-
body (B4) show that there is strong staining for apoB in
close proximity to the nucleus in both STP-O– and sapo-
nin-permeabilized HepG2 cells. The stronger signal for
apoB in this location (compared with that in the remaining
secretory pathway) suggests that this region is the site for
apoB synthesis. A location for apoB synthesis close to the
nuclear membrane was also observed in the immunocy-
tochemical studies of Keller et al. (1986), who transiently
depleted rat hepatocytes of apoB and other secretory pro-
teins by incubating cells with cycloheximide. After cyclo-
heximide washout, strong labeling of apoB that did not
overlap with albumin labeling was observed in the vicinity
of the nuclear envelope (Keller et al., 1986). Therefore, it
appears that a significant portion of apoB is synthesized in
the area of the ER that is localized close to the outer mem-
brane of the nuclear envelope. An intriguing hypothesis is
that the very large apoB mRNA does not diffuse far from
nuclear membrane pores. This hypothesis is supported by
observations that the mRNA for apoB gives a nonclassical
distribution among polysomes/monosomes in sucrose gra-
dients (Chen et al., 1993). The widespread staining for
apoB in the extensive reticular network represents apoB
that has escaped degradation in the ER and is now located
in other compartments of the secretory pathway where ad-
ditional lipids are acquired and lipoprotein particle matu-
ration occurs (Alexander et al., 1976; Higgins, 1988; Bam-
berger and Lane, 1990).
Another finding in this study was the identification of
two domains of apoB that are exposed to the cytosol
throughout a large portion of the secretory pathway: in
ER membranes in close proximity to the nuclear outer
membrane, in other ER membranes, and in other com-
partments of the secretory system. The B4 antibody (rec-
ognizing amino acids 3221–3240) was specifically raised to
a strongly hydrophillic domain in apoB juxtaposed next to
a highly hydrophobic domain (Fig. 1). We hypothesized
that such a hydrophilic region in apoB may be exposed on
the cytosolic face of the ER membrane after nonclassical
spanning of the ER membrane by multiple hydrophobic
domains of apoB. The similar intensity of staining of apoB
obtained with the B4 antibody in both STP-O– or saponin-
permeabilized cells is strong evidence that this domain is
exposed to the cytosol throughout the secretory pathway.
Any additional detergent or disrupting activity afforded
by saponin only slightly increased the signal due to the
binding of the B4 antibody to this domain of apoB by
Figure 9. Dual localization
of B4 and CC3.4 domains in
apoB in STP-O–permeabi-
lized cells. HepG2 cells were
permeabilized with STP-O
and probed simultaneously
with monoclonal CC3.4 (1/
100) and affinity-purified
rabbit anti-B4 peptide anti-
body (1/25). After washing, the cells were incubated with the appropriate secondary antibodies conjugated with different fluorochromes
and examined at 570 nm (A, green; CC3.4 monoclonal) and 680 nm (B, red; anti-B4 peptide). The digital images were superimposed, and
significant overlap is denoted by yellow (C).
Figure 10. Localization of a
COOH-terminal region of
apoB in lysosomes. HepG2
cells were permeabilized





antibody, and with mono-
clonal B1B6 anti-apoB. After
washing, the cells were incu-
bated with the appropriate
secondary antibodies conju-
gated with different fluoro-
chromes and examined at
570 nm (A, green; sheep poly
anti-human LDL) or at 680
nm (B, red; monoclonal B1B6). The digital images were superimposed, and significant overlap is colored yellow (C). (D–F) STP-
O–treated cells were probed simultaneously with the affinity-purified sheep polyclonal anti-human LDL antibody and monoclonal
H4A3 to LAMP-1. After washing, the cells were incubated with the appropriate secondary antibodies conjugated with different fluoro-
chromes, and were examined at both 570 nm (D, green; sheep polyclonal anti-human LDL) or at 680 nm (E, red; monoclonal anti-
LAMP-1). The digital images were superimposed, and significant overlap is yellow (F).
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z10% (Fig. 7). The domain recognized by the CC3.4 mono-
clonal antibody was also cytosolic (Fig. 8). The region in
apoB identified by this antibody is a region of apoB that
has been previously proposed to be cytosolic (Du et al.,
1994).
Unlike a typical secretory protein, apoB contains pause-
transfer sequences that cause apoB to pause transiently as
it translocates during translation through the aqueous pro-
tein–conducting channel of the ER (Chuck et al., 1990;
Hegde and Lingappa, 1996). Domains of apoB become ex-
posed to the cytosol when the ER membrane–ribosome
junction opens during translocation pausing (Hegde and
Lingappa, 1996). Pause transfer sequences are asymmetri-
cally distributed throughout apoB (Kivlen et al., 1997). Of
the 23 pause transfer sequences noted, nine are located in
the first 20% of the apoB molecule, four are near the
apoB48 junction, and ten are found between apoB65 and
apoB95. Three (B167.6, B169.5, and B173.1) occur near the
B4 site in apoB at B171.2. Translocation pausing may be
the mechanism by which certain domains of apoB remain
exposed to the cytosol, allowing access to cytosolic chaper-
ones (Zhou et al., 1995) or the components of the protea-
some degradation system (Yeung et al., 1996; Fisher et al.,
1997; Benoist and Grandperret, 1997).
In contrast to the anti-B4 and CC3.4 antibodies, neither the
polyclonal anti-human LDL antibody (Fig. 7 E), the D7.2
monoclonal (Fig. 8 C), or the monoclonal antibody B1B6
(Fig. 10 B) produced a signal for apoB in the perinuclear
region or a reticular ER staining pattern in the intermedi-
ate regions of the secretory pathway in STP-O–permeabi-
lized cells. The region identified by the D7.2 monoclonal
was not exposed to the cytosol, but was most probably lu-
menal as strong signals were observed in saponin-treated
cells (Fig. 8 D). The anti-LDL and B1B6 monoclonal anti-
bodies produced similar punctate patterns throughout the
cytoplasm in STP-O–permeabilized cells. The regions of
apoB identified by these antibodies are either not exposed
to the cytosol, or if on the cytosolic face of membranes of
the secretory pathway, are not available for antibody bind-
ing. The lack of staining for apoB by either polyclonal
anti-human LDL antibodies tested (one raised in a sheep;
the other in a rabbit) in membranes of STP-O–permeabi-
lized cells was at first difficult to understand. Additional
studies with this antibody involving probing for apoB in a
diverse series of nonhepatic cell lines indicated that the
sheep polyclonal anti-LDL antibody recognizes mature
domains of apoB that are properly processed (data not
shown). It was concluded that all of the epitopes in apoB
recognized by the sheep anti-LDL antibody are lumenally
exposed as they are only observed when cell membranes
are perforated with saponin. The relatively low signal pro-
duced by the polyclonal anti-LDL antibody throughout
the entire interior of STP-O–treated cells (except for the
punctate areas) is additional evidence that membranes of
the secretory pathway were not perforated in STP-O–per-
meabilized cells. Interestingly, the B1B6 antibody, unlike
the D7.2 antibody, did not produce a reticular staining pat-
tern in saponin-permeabilized cells, indicating that the
epitope in apoB recognized B1B6 is not available for anti-
body binding throughout the entire secretory pathway,
even when internal membranes are perforated by saponin.
The identical punctate patterns of staining observed with
both polyclonal anti-LDL antibodies (one raised in a rabbit,
the other raised in a sheep) and the B1B6 monoclonal
anti-apoB antibody are strong evidence that these anti-
bodies are binding to apoB, and are not binding nonspecif-
ically to other proteins located in the lysosome. Additional
evidence for this conclusion is that the B1B6 antibody did
not produce an equivalent punctate, lysosomal staining
pattern in human HeLa and 1321N1J astrocytoma cells, in-
dicating that B1B6 is not binding to a constitutive lysoso-
mal membrane protein (data not shown). The punctate
signal produced by the B1B6 antibody suggests that this
region of apoB in some apoB molecules may be eventually
degraded in lysosomes.
The observations in the current study and in previous
reports can be used to derive partially the transmembrane
structure of apoB in the secretory pathway of HepG2 cells.
Previous studies (Du et al., 1994) provided data that the
amino terminal of apoB was lumenal, and that apoB could
be cleaved by exogenous trypsin at a cytosolic site at z70
kD. This led to a model of apoB conformation where only
70 kD of the amino terminus of apoB was translocated,
while the remaining portion of the apoB polypeptide was
exposed to the cytosol (Du et al., 1994).
Our protease protection assays using ALLN to stabilize
exogenous protease-cleaved fragments of apoB from en-
dogenous proteases indicated that there are probably two
major regions of apoB susceptible to proteinase K on the
cytosolic surface of the ER membrane. The most promi-
nent bands observed were at z387 (size deduced from
comigration with the major thrombin cleavage product as
shown in Fig. 4) and 150 kD, polypeptide fragments that
fit with a cytosolically exposed region of apoB at the
epitope site of the B4 peptide at amino acids 3221–3240
(approximately B71 in the centile nomenclature). The
lighter bands observed (Fig. 4) could be the result of an-
other cleavage site at z70 kD, agreeing with the immuno-
cytochemistry data (Fig. 8 A) showing that the CC3.4 site
is cytosolically exposed, and the previous data of Du et al.
(1994) showing an exposed site in apoB at z70 kD. Using
the pattern of peptides generated by PK and the results
from the antibodies used in the immunocytochemistry
study, a putative model for the conformation of apoB in
the ER membrane can be drawn (Fig. 11). During early
translation, a region of apoB is exposed on the cytosolic
side of the ER membrane, and may provide the opportu-
nity for cotranslational degradation; possibly through a
ubiquitin proteasome–dependent process (Fig. 11 [1]). Re-
cent studies by Benoist and Grandperret (1997) suggested
that apoB can be degraded by the proteasome cotransla-
tionally when an apoB molecule of about the size of B65 is
attained. The current study shows that after complete
translation, most of apoB is lumenal except for two rela-
tively short regions at z70–90 kD (including the CC3.4
site) and at the B4 epitope site (at about B71; Fig. 11 [2]).
The D7.2 and B1B6 epitopes and multiple epitopes (w)
recognized by the affinity-purified polyclonal antibody are
not available from the cytosol or, as shown in the diagram,
are located on the luminal side of the ER. ApoB that is
made into a nascent lipoprotein leaves the vicinity of cer-
tain ER proteases (Sakata et al., 1993; Adeli et al., 1997)
and traverses the secretory pathway (Fig. 11 [3a]). Pulse-
chase studies indicated that full-sized apoB can be rapidly
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degraded in the ER compartment of HepG2 cells (Fu-
rukawa et al., 1992). This degradation may be accom-
plished by a retrograde transport mechanism that directs
apoB to the proteasome (Fig. 11 [3b]). Export of proteins
from the ER to the cytosol for degradation by protea-
somes has recently been shown to involve the translocon
in both mammalian cells (Wiertz et al., 1996) and in yeast
(Pilon et al., 1997). The mechanism used by apoB is not
known. It appears that a region of apoB that in part com-
prises the B1B6 epitope, may escape degradation by the
proteasome (Fig. 11 [4]), and is transported to the lyso-
some where it can be observed cytosolically exposed on
the lysosomal membrane (Fig. 11 [5]). In this model, early
degradation of a majority of the apoB molecules in the ER
may at first involve a specific protease (Adeli, 1994; Adeli
et al., 1997) and later the cytosolic proteasome (Fisher et al.,
1997). The depiction of apoB as cytosolically exposed at
only two small regions may require modification as more
information on cytosolic sites in apoB becomes available.
Studies using an ELISA to probe exposed apoB in isolated
cell fractions (Wilkinson et al., 1993) indicated that the
NH2-terminal 48%, NH2-terminal 48–74%, and the COOH-
terminal 25% regions of membrane-bound apoB were
fairly prominently exposed to the cytosol in RER, SER,
and Golgi fractions. The current results generally agree
with these observations, but more precisely localize the ex-
posed domains in apoB. The previous results (Wilkinson
et al., 1993) indicate that a region of apoB more COOH-
terminal than the B4 and B1B6 domains is also transmem-
brane. 
The current results with protease protection assays in
permeabilized cells (Fig. 5) agree with the results obtained
in a previous study (Macri and Adeli, 1997) at earlier
chase times (5–10 min), but differ at a longer chase time
(30 min). In digitonin-permeabilized HepG2 cells that had
been treated with 10 mM ALLN and oleate, apoB was
highly susceptible to exogenous trypsin after a 5-min
chase, but became largely resistant to trypsin after 30 min
of chase. These studies (Macri and Adeli, 1997) showed
that the translocation of apoB was mostly complete after
30 min of chase time. It is not clear why our results differ
at 30 min, but the immunocytochemical observations sup-
port the time course protease protection assay experiment
(Fig. 5), indicating that apoB maintains a transmembrane
orientation throughout extensive parts of the secretory
pathway.
The current results suggest that small regions of most
apoB molecules are transmembrane, and remain so until
dislodgement for secretion or degradation later in the
secretory pathway. This concept/model is different from
previous models that indicated that all apoB molecules are
fully cotranslationally translocated across the ER mem-
brane, or that only apoB molecules destined for secretion
are cotranslationally translocated across the ER mem-
brane. The current model is consistent with the following
processes observed experimentally: (a) ApoB is predomi-
nately a transmembrane protein in the membranes of the
secretory pathway (reviewed in Yao et al., 1997). (b)
ApoB in certain hepatic cell models can be rapidly de-
graded in an early secretory compartment (Sato et al.,
1990; Dixon et al., 1991; Furukawa et al., 1992; White et
al., 1992), most likely through several process including
one that involves tagging by a cytosolic chaperone fol-
lowed by degradation using the ubiquitin/proteasome sys-
tem (Zhou et al., 1995; Yeung et al., 1996; Fisher et al.,
1997; Benoist and Grandperret, 1997). (c) In the presence
of ALLN, completely translated apoB molecules that
would have been destined for degradation without ALLN
Figure 11. Model of apoB
structure in the membrane of
the endoplasmic reticulum.
The diagram shows a puta-
tive model of nascent apoB
in the ER membrane. Path-
ways are explained in the text.
Putative epitopes for the
polyclonal anti-LDL antibod-
ies are shown (w). The shaded
ovals represent chaperon
proteins, including heat shock
protein 70. The circles with a
missing wedge represent pu-
tative proteases in the ER.
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retain the capacity to form an apoB lipoprotein that is se-
creted when lipid synthesis is increased at a later time pe-
riod (Sakata et al., 1993). This capacity would reinforce
the concept that apoB molecules that are transmembrane
after translation are not totally marked for degradation.
(d) ApoB can also be degraded later in the secretory path-
way, especially in rat hepatocytes (Wang et al., 1995; Cart-
wright and Higgins, 1996; Sparks et al., 1996). (e) A trans-
membrane region in apoB at the B4 epitope (B71) would
explain the differences observed in the susceptibility of rat
apoB100 and apoB48 to exogenous trypsin. In a series of
studies (Rusinõl et al., 1993b; Wang et al., 1995; McLeod
et al., 1996), apoB48 was almost totally resistant to trypsin,
but apoB100 was almost 100% susceptible. These observa-
tions lead to the conclusion that only apoB100 exists as a
transmembrane protein, and that membranes in the pre-
pared microsomes were not perforated because B48 was
not degraded in the same protease protection assay incu-
bation.
In summary, the results identify two specific regions in
apoB that are exposed to the cytosol in the secretory path-
way. A transmembrane orientation may be important in the
regulation of apoB in the following ways: ApoB would re-
main in close proximity to the ER membrane so that it
could be efficiently lipidated by microsomal triglyceride
transfer protein, and routed correctly to the appropriate ER
to Golgi secretory vesicle. The transmembrane nature of
poorly lipidated apoB molecules would aid in targeting these
molecules for degradation both early (ER) and late (Golgi
or lysosomal compartments) in the secretory pathway.
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